TMEM242: A Potential Drug Target and Biomarker for Diseases (G729515)

Target Name: TMEM242

NCBI ID: G729515

TMEM242

TMEM242: A Potential Drug Target and Biomarker for Diseases

TMEM242 (BM033) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the superfamily of transmembrane protein (SMP) family and is characterized by the presence of a transmembrane domain and a cytoplasmic tail. TMEM242 is involved in a variety of physiological processes in the body, including cellular signaling, inflammation, and stress response.

TMEM242 has been identified as a potential drug target due to its unique structure and its involvement in several diseases. One of the main reasons for its potential as a drug target is its unique structure. TMEM242 consists of a transmembrane domain that is made up of four conserved amino acids: alanine, glutamic acid, aspartic acid, and glycine. The cytoplasmic tail of TMEM242 consists of a unique farnesylated cysteine residue that is involved in protein-protein interactions and may play a role in the regulation of cellular signaling pathways.

Another reason for TMEM242's potential as a drug target is its involvement in several diseases. For example, TMEM242 has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, TMEM242 has been associated with inflammation and stress response, which may contribute to the development of certain diseases. For example, TMEM242 has been shown to be involved in the regulation of inflammation and has been shown to play a role in the stress response to stress.

In addition to its potential as a drug target, TMEM242 has also been shown to be a valuable biomarker for several diseases. For example, TMEM242 has been shown to be an effective biomarker for the diagnosis of neurodegenerative diseases, such as Alzheimer's disease. Additionally, TMEM242 has been shown to be a valuable biomarker for the diagnosis of certain infections, such as sepsis.

TMEM242 is also a good candidate for a diagnostic diagnostic biomarker for cancer, as it has been shown to be expressed in the brains of several types of cancer. This suggests that it may be a useful diagnostic tool for cancer patients.

In conclusion, TMEM242 is a protein that has unique structure and is involved in several physiological processes in the body. It has been identified as a potential drug target due to its structure and its involvement in several diseases. In addition to its potential as a drug target, TMEM242 has also been shown to be a valuable biomarker for several diseases, including neurodegenerative diseases, cancer, and stress response. Further research is needed to fully understand the role of TMEM242 in the body and its potential as a drug and diagnostic tool.

Protein Name: Transmembrane Protein 242

Functions: Scaffold protein that participates in the c-ring assembly of mitochondrial ATP synthase (F(1)F(0) ATP synthase or complex V) by facilitating the membrane insertion and oligomer formation of the subunit c/ATP5MC3 (PubMed:33753518). Participates in the incorporation of the c-ring into vestigial complexes (PubMed:33753518). Additionally influences the incorporation of subunits MT-ATP6, MT-ATP8, ATP5MJ, and ATP5MK in the ATP synthase (PubMed:33753518)

The "TMEM242 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM242 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets